Drugs / MRX-2843
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04872478 | Apr 2022 → Jul 2026 overdue | acute lymphoblastic leukemia, mixed phenotype acute leukemia | Meryx, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04762199 | Feb 2021 → Dec 2026 expected | non-small cell lung carcinoma | Emory University | Recruiting | No outcome recorded |
| Phase 1 | NCT03510104 | May 2018 → Dec 2025 | cancer of unknown primary site, metastatic malignant neoplasm | Meryx, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04946890 | Jul 2021 → Dec 2024 | acute myeloid leukemia | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRX-2843 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03510104 ↗ |
| Known as | UNC-2371A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650408 ↗ |
| Action | Inhibit | “MRX-2843 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.” NCT04762199 ↗ |
| Route | Oral | “Patients receive osimertinib orally (PO) once daily (QD) and MRX-2843 PO QD on days 1-28.” NCT04762199 ↗ |
| Target | FLT3 | “Flt3/MerTK Inhibitor MRX-2843” NCT04762199 ↗ |
| Target | MERTK | “Flt3/MerTK Inhibitor MRX-2843” NCT04762199 ↗ |